Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company’s Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., to succeed Dr. Dube as president and chief executive officer and a member of the Board, effective December 1, 2026. Dr. Dube will continue to serve as president and chief executive officer until that date and will remain employed by the Company as executive advisor through February 15, 2027, to support an orderly transition.